FDA Approves Groundbreaking New Melanoma Treatment Amtagvi
• FDA granted accelerated approval for Iovance's melanoma treatment, Amtagvi
• Amtagvi is the first individualized T-cell therapy approved for a solid tumor
• Amtagvi projected to generate $900M in annual sales by 2029
• Iovance announced $211M stock offering to support Amtagvi commercial launch
• Stock has already priced in much expected growth, but more catalysts possible